We use cookies to display personalized content, analyze site traffic, provide recommendations, and ensure you have a great browsing experience. By continuing to use our site, you consent to our use of cookies. Privacy Policy.
Bringing a medical device to the U.S. market requires FDA clearance, and for most Class II devices, that means a successful medical device 510(k) submission. The process demands precision; from device classification and predicate selection to a documentation package the FDA can act on. QSS guides manufacturers, companies, and international brands through the 510(k) pathway with clarity.
The 510(k) premarket notification process requires manufacturers to demonstrate that their device is substantially equivalent to a legally marketed predicate. That standard sounds straightforward until you’re choosing between multiple predicates, reconciling performance data, or navigating FDA’s expectations for a particular device category. A submission that isn’t structured correctly doesn’t just slow your clearance down. It creates a paper trail the FDA will reference for every future interaction.
For companies entering the U.S. market from Canada or internationally, FDA establishment registration, U.S. agent requirements, and post-clearance obligations mean the compliance picture is broader than the submission itself. Getting the 510(k) right from the start protects your market entry timeline and positions your device program for scale.
Most device companies only go through this process once or twice. QSS has guided hundreds of submissions across device categories, and that pattern recognition is what changes outcomes.
Before any submission work begins, we assess your device classification, identify viable predicate devices, and map the evidence gaps that need to be resolved. You get a clear picture of what the submission requires before investing in preparation, and no surprises mid-process.
Selecting the right predicate is one of the most consequential decisions in your 510(k). We analyze the regulatory history, performance characteristics, and intended use of candidate predicates to build the strongest possible equivalence argument. When multiple predicates are viable, we advise on the strategy with the clearest path to 510(k) clearance.
We compile and structure the complete 510(k) submission package — device description, substantial equivalence summary, performance testing protocols, biocompatibility data, labeling review, and all required sections — in alignment with current FDA guidance. Our team reviews for completeness before submission so nothing is left to chance.
When the FDA issues an Additional Information (AI) request, the clock is running and the stakes are high. We draft and review responses to FDA deficiencies, clarify technical positions, and work through the review process with you. Clients don’t navigate that stage alone.
Software-driven devices and digital health tools follow distinct guidance under FDA’s SaMD framework. We advise on software documentation requirements, cybersecurity considerations, and the predicate pathway for connected and software-based devices seeking FDA clearance.
When no valid predicate exists, the De Novo pathway provides an alternative route to market for novel low-to-moderate risk devices. We evaluate De Novo eligibility and, where appropriate, prepare and support the classification request — including the special controls framework that follows.
510(k) clearance is the beginning of your FDA relationship, not the end. We advise on device modifications that may trigger a new submission, support labeling updates, and help clients maintain ongoing compliance with FDA’s post-market requirements.
A 510(k) is a premarket submission that device manufacturers file with the FDA to demonstrate their device is substantially equivalent to a legally marketed device already on the U.S. market. Most Class II medical devices require 510(k) clearance before they can be legally sold in the United States. Some Class I devices with special controls and certain device modifications may also trigger a submission requirement.
The standard FDA review target is 90 days from acceptance, but total elapsed time is typically longer when you account for acceptance review, any holds, and Additional Information requests. Complex devices, inadequate documentation, or deficiency responses that don’t fully address FDA’s questions can extend the timeline significantly. Submissions built to FDA’s current guidance and reviewer expectations tend to move through the process with fewer interruptions.
No. Device labeling for the U.S. market must comply with FDA requirements, which differ from other regulatory frameworks. This includes specific requirements for device identification, intended use statements, directions for use, and any claims. A label approved in another country does not automatically satisfy FDA standards, and non-compliant labeling can delay clearance or result in import refusal. QSS can review your label and Instructions for Use (IFU) to confirm they meet FDA requirements before your submission or market entry.
Substantial equivalence means your device has the same intended use as the predicate and the same or equivalent technological characteristics, or that any differences don’t raise new safety or effectiveness questions. Establishing it requires selecting the right predicate device, comparing performance data, and structuring the equivalence argument clearly. The choice of predicate is one of the most strategically important decisions in the entire 510(k) process.
Some device companies with dedicated regulatory affairs staff can prepare 510(k) submissions internally. The practical question is whether your team has prepared submissions for your specific device category, has current familiarity with FDA’s documentation expectations, and has capacity to manage a deficiency response without pulling resources from other priorities. Many companies find that working with an experienced FDA 510(k) consultant reduces risk and total time to clearance, especially for first U.S. submissions.
A deficiency letter means the FDA has questions about your submission that need to be addressed before review can continue. You typically have a set timeframe to respond, and the quality of that response directly affects whether the review moves forward. An incomplete or unclear response can restart the clock. This is a stage where preparation and experienced guidance makes a measurable difference.
Yes, international manufacturers can submit a 510(k) directly to the FDA, but a U.S. Agent is required and FDA establishment registration must be completed before submission. Understanding U.S. labeling requirements, FDA’s documentation standards, and post-clearance obligations is critical. QSS regularly works with international device companies navigating U.S. market entry from outside North America.
De Novo is an FDA classification pathway for novel devices that don’t have a valid predicate but present low to moderate risk. It’s the appropriate route when the 510(k) pathway isn’t available because the device is genuinely new, not a variation on something already cleared. De Novo classification takes longer and involves a more detailed review than 510(k), but it establishes the device as a predicate for future submissions.